Impact of subtypes and comorbidities on breast cancer relapse and survival in population-based studies. (October 2018)

• Record Type: Journal Article
• Authors: Ess, Silvia M.; Herrmann, Christian; Bouchardy, Christine; Neyroud, Isabelle; Rapiti, Elisabetta; Konzelmann, Isabelle; Bordoni, Andrea; Ortelli, Laura; Rohrmann, Sabine; Frick, Harald; Mousavi, Mohsen; Thürlimann, Beat
• Is Part Of: Breast. Volume 41(2018)
• Page Start: 151
• Page End: 158
• Publication Date: 2018-10
• Subjects: Breast cancer subtypes -- Distant relapse -- Locoregional relapse -- Breast cancer survival -- Population-based study -- Switzerland; Breast -- Diseases -- Periodicals; Breast -- Tumors -- Periodicals; Breast -- Periodicals; Electronic journals; Periodicals; 616
• DOI: 10.1016/j.breast.2018.07.011
• Languages: English
• ISSNs: 0960-9776

Abstract

Abstract: Objective: To study the impact of subtypes and comorbidities on breast cancer (BC) relapse and survival in the heterogeneous patients of the real world. Methods: We identified patients diagnosed with BC between January 2003 and December 2005 from six population-based Swiss cancer registries. Clinicopathologic data was completed with information on locoregional and distant relapse and date and cause of death for over 10-years. We approximated BC subtypes using grade and the immunohistochemical panel for oestrogen, progesterone and human epidermal growth factor 2 (HER2) receptor status. We studied factors affecting relapse and survival. Results: Luminal A-like subtype represented 46% of all newly diagnosed BC (N = 1831), followed by luminal B-like (N = 1504, 38%), triple negative (N = 436, 11%) and HER2 enriched (N = 204, 5%). We observed regional disparities in subtype prevalence that contribute to explain regional differences in survival formerly described. Disease relapse and BC specific mortality differed by subtype and were lower for luminal A like tumours than for other subtypes for any stage at diagnosis. After a median follow-up of 10.9 years, 1311 (33%) had died, half of them 647 (16%) due to another disease, showing the importance of comorbidities. Omission of systemic therapies in selected patients was not associated with poorer BC specific survival, BC subtype and life expectancy playing a role. Conclusions: Information on tumour subtype is necessary for an adequate interpretation of population-based BC studies. Measures of comorbidity or frailty help in the evaluation of quality of care in the highly heterogeneous patients of the real world. Highlights: Breast cancer relapse and survival differ by both subtype and stage at diagnosis. Luminal A-like is the most frequent subtype and regional differences are present. At any stage, luminal A like tumours have better prognosis. The impact of substandard therapies differs according to subtype and life expectancy.